MIF098

Research use only, not for human use.

MIF098, a macrophage migration inhibitory factor (MIF) antagonist, inhibits pulmonary hypertension associated with SLE and the proliferation and migration of pulmonary arterial smooth muscle cells (PASMC).

MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.

MIF098 (0-10 μM, 48 h) inhibits mPASMC cell proliferation and migration in a concentration-dependent manner, by blocking the migration inhibitory factor (MIF) pathway.MIF098 reduces collagen synthesis and pulmonary artery fibrosis by inhibiting the TGFβ1/Smad2/3 pathway.Western Blot Analysis Cell Line:Mouse pulmonary artery smooth muscle cells (mPASMCs)Concentration:0-10 μM Incubation Time:48 hours Result:Reduced expression of cell cycle related proteins such as cyclin D1, CDK4 and CDK6 in PDGF-BB and increased expression of cell-cycle arrest proteins such as P53 and P21.Reduced TGFβ1-induced fibronectin (FN), collagen I (col I), and collagen II (col II) expression and phosphorylation of Smad2 and Smad3.

MIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice.Animal Model:Hypoxic male C57BL/6J mice Dosage:40 mg/kg Administration:Intraperitoneal injection; once a day; 4 weeks Result:Reduced right ventricular systolic pressure (RVSP), percentage medial wall thickness, muscularization and right ventricle collagen deposition.Decreased percentage of collagen fibers in pulmonary artery (PA).

——

Others

Other Targets

Others

——

——

1208448-95-6

255.27

C15H13NO3

>98% (HPLC)

In Vitro:?DMSO : 180 mg/mL (705.14 mM; Ultrasonic (<60°C)

Cc1ccc2oc(=O)n(Cc3cccc(O)c3)c2c1

——

(-20℃)

With Ice Pack

≥ 2 years